LDS/Medical Tests/Butabarbital, Urine

Butabarbital, Urine

Butabarbital is classified as a barbiturate, which is one of the oldest classes of CNS depressant and is primarily used as treatment for insomina.  Butabarbital is available as a capsule or suspension taken orally.

Barbiturates can be administered either orally or parentally. Barbituates undergo extensive hepatic metabolism. The intravenous route of administration is used to administer the ultrashort-acting barbiturates for induction of anesthesia. Barbiturates can elicit the following side effects: amnesia, hostility, irritability, Stevens-Johnson syndrome and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, incoordination, slow speech, impaired thinking, bradycardia, tachycardia, coma, and possible death.

Numerous methods are available to screen for barbiturate use.  Generally, immunoassays are used with antibodies that are directed toward secobarbital, and thus rely on degrees of cross-reactivity to the remaining drugs or active metabolites.  Confirmation testing can be performed by a variety of analytical methods such Gas Chromatography/Mass Spectroscopy (GC/MS) and Liquid Chromatography/Mass Spectroscopy (LC/MS).

  • Therapeutic monitoring in blood samples
  • Drug abuse evaluation
  • Toxicity assessment in blood samples
  • Patient Compliance
A qualitative positive result from an immunoassay type test indicates only the presence of the barbiturates including Amobarbital and does not necessarily correlate with the extent of physiological and psychological effects. Any positive screening result must be confirmed by a confirmatory non-immunological method such as LC/MS or GC/MS.

Therapeutic levels

Butabarbital intermediate acting class: 1-5.0 mg/L    

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

 

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as TLC or IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

 

 

Liquid Chromatography/Mass Spectroscopy (LC/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Immunoassay (IA). The main method of quantification is via mass spectrometry based methods, either GC/MS or LC/MS. These particular methods of analysis can be used to not only detect the parent drug class of barbiturates, but also the major metabolites. Butabarbital, similar to all barbiturates, can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. Butabarbital is not extensively bound to protein and usually appears in the urine as the glucuronide conjugate. When analyzing urine specimens a hydrolysis step is required if removal of the glucuronide conjugate is desirable.  Enzymatic hydrolysis is preferred over acid hydrolysis.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3 days
  • Refrigerated: 14 days
  • Frozen: 14 days
Pain drug management pharmacogenomics panel or CYP3A4, CYP3A5, CYP2D6 may be tested for drug safety and efficacy before prescribing barbituates.  Supportive testing such as Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC (if overdose), other drugs if necessary.
1-3 days
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
  • Ann Clin Biochem. 1997 Sep;34 ( Pt 5):460-510. [PMID: 9293303]
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Urine Testing for Drug Abuse. National Institute on Drug Abuse (NIDA) Research Monograph. 1986;73.
  • Baselt RC, Ed. Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology, 2nd ed. Littleton, MA: PSG Publishing Co. (1987).
  • Principles of Forensic Toxicology, Fourth Edition, Ed, Barry Levine. AACC Press, Washington DC. Chapter 14, Benzodiazepines, pp. 237-251 2013).
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, Eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
  • Baselt RC, Ed. Disposition of Toxic Drugs and Chemicals in Man, 6th ed. Foster City, CA: Biomedical Publications (2002).
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79 Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4): 7-20.